Segall Bryant & Hamill’s Cytokinetics CYTK Stock Holding History

Segall Bryant & Hamill’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$21.9M	Buy	257,063 +76,863	+43%	+$5.52M	0.26%	137
2026 Q1	$11.9M	Sell	180,200 -9,313	-5%	-$592K	0.17%	202
2025 Q4	$12M	Buy	189,513 +8,463	+5%	+$526K	0.16%	206
2025 Q3	$9.95M	Buy	181,050 +97,280	+116%	+$4.01M	0.13%	239
2025 Q2	$2.77M	Buy	83,770 +14,227	+20%	+$495K	0.04%	384
2025 Q1	$2.79M	Sell	69,543 -1,957	-3%	-$89.9K	0.04%	386
2024 Q4	$3.36M	Sell	71,500 -951	-1%	-$49.4K	0.05%	388
2024 Q3	$3.83M	Sell	72,451 -2,947	-4%	-$164K	0.05%	365
2024 Q2	$4.09M	Buy	+75,398	New	+$4.55M	0.07%	322

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Segall Bryant & Hamill's CYTK Position: Q2 2026 in Review

Segall Bryant & Hamill increased its Cytokinetics (CYTK) stake by 43% in Q2 2026, buying an estimated $5.52M and bringing the position to 257,063 shares worth $21.9M. The position accounts for 0.26% of the portfolio, ranked #137.

Segall Bryant & Hamill first reported a position in CYTK in Q2 2024 and has held it in 9 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Segall Bryant & Hamill held 257,063 shares of Cytokinetics worth $21.9M as of Q2 2026.
Segall Bryant & Hamill bought 76,863 Cytokinetics shares in Q2 2026, an estimated $5.52M.
Cytokinetics made up 0.26% of Segall Bryant & Hamill's portfolio in Q2 2026, its #137 holding.
Segall Bryant & Hamill first reported a position in Cytokinetics in Q2 2024 and has held it in 9 quarters since.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Segall Bryant & Hamill's 13F filing for Q2 2026, filed 12 Aug 2026.